

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number
WO 2004/018434 A1

(51) International Patent Classification⁷: **C07D 239/42**,
401/12, A61K 31/505, 31/506, A61P 25/06

(21) International Application Number:
PCT/EP2003/009221

(22) International Filing Date: 19 August 2003 (19.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0219500.6 21 August 2002 (21.08.2002) GB
0316332.6 11 July 2003 (11.07.2003) GB

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EATHERTON, Andrew, John** [GB/GB]; GlaxoSmithKline, The Frythe, Welwyn, Hertfordshire AL6 9AR (GB). **GIBLIN, Gerard, Martin, Paul** [GB/GB]; GlaxoSmithKline, The Frythe, Welwyn, Hertfordshire AL6 9AR (GB). **GREEN, Richard, Howard (Deceased)** [GB/GB]; c/o GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **MITCHELL, William, Leonard** [GB/GB]; GlaxoSmithKline, The Frythe, Welwyn, Hertfordshire AL6 9AR (GB). **NAYLOR, Alan** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **RAWLINGS, Derek, Anthony** [GB/GB]; GlaxoSmithKline, The Frythe, Welwyn, Hertfordshire AL6 9AR (GB). **SLINGSBY, Brian**,

Peter [GB/GB]; GlaxoSmithKline, The Frythe, Welwyn, Hertfordshire AL6 9AR (GB). **WHITTINGTON, Andrew, Richard** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).

(74) Agent: **HOCKLEY, Sian, Catherine**; GlaxoSmithKline, CIP (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRIMIDINE COMPOUNDS

(57) Abstract: The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

WO 2004/018434 A1

PYRIMIDINE COMPOUNDS

The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

Cannabinoids are a specific class of psychoactive compounds present in Indian cannabis (*Cannabis sativa*), including about sixty different molecules, the most representative being cannabinal, cannabidiol and several isomers of tetrahydrocannabinol. Knowledge of the therapeutic activity of cannabis dates back to the ancient dynasties of China, where, 5,000 years ago, cannabis was used for the treatment of asthma, migraine and some gynaecological disorders. These uses later became so established that, around 1850, cannabis extracts were included in the US Pharmacopoeia and remained there until 1947.

Cannabinoids are known to cause different effects on various systems and/or organs, the most important being on the central nervous system and on the cardiovascular system. These effects include alterations in memory and cognition, euphoria, and sedation. Cannabinoids also increase heart rate and vary systemic arterial pressure. Peripheral effects related to bronchial constriction, immunomodulation, and inflammation have also been observed. The capability of cannabinoids to reduce intraocular pressure and to affect respiratory and endocrine systems is also well documented. See e.g. L.E. Hollister, Health Aspects of Cannabis, Pharmacological Reviews, Vol. 38, pp. 1-20, (1986). More recently, it was found that cannabinoids suppress the cellular and humoral immune responses and exhibit antiinflammatory properties. Wirth et al., Antiinflammatory Properties of Cannabichrome, Life Science, Vol. 26, pp. 1991-1995, (1980).

In spite of the foregoing benefits, the therapeutic use of cannabis is controversial, both due to its relevant psychoactive effects (causing dependence and addiction), and due to manifold side effects that have not yet been completely clarified. Although work in this field has been ongoing since the 1940's, evidence indicating that the peripheral effects of cannabinoids are directly mediated, and not secondary to a CNS effect, has been limited by the lack of receptor characterization, the lack of information concerning an endogenous cannabinoid ligand and, until recently, the lack of receptor subtype selective compounds.

The first cannabinoid receptor was found to be mainly located in the brain, in neural cell lines, and, only to a lesser extent, at the peripheral level. In view of its location, it was called the central receptor ("CB1"). See Matsuda et al., "Structure of a Cannabinoid Receptor and Functional Expression of the Cloned cDNA," Nature, Vol. 346, pp. 561-564 (1990). The second cannabinoid receptor ("CB2") was identified in the spleen, and was assumed to modulate the non psychoactive effects of the cannabinoids. See Munro et al., "Molecular Characterization of a Peripheral Receptor for Cannabinoids," Nature, Vol. 365, pp. 61-65 (1993).

Recently, some compounds have been prepared which are capable of acting as agonists on both the cannabinoid receptors. For example, use of derivatives of dihydroxypyrrole-(1,2,3-d,e)-1,4-benzoxazine in the treatment of glaucoma and the use of derivatives of 1,5-diphenylpyrazole as immunomodulators or psychotropic agents in the treatment of various neuropathologies, migraine, epilepsy, glaucoma, etc are known. See U.S. Patent No. 5,112,820

and EP 576357, respectively. However, because these compounds are active on both the CB1 and CB2 receptor, they can lead to serious psychoactive effects.

The foregoing indications and the preferential localization of the CB2 receptor in the immune system confirms a specific role of CB2 in modulating the immune and antiinflammatory response to stimuli of different sources.

The total size of the patient population suffering from pain is vast (almost 300 million), dominated by those suffering from back pain, osteo-arthritic pain and post-operative pain. Neuropathic pain (associated with neuronal lesions such as those induced by diabetes, HIV, herpes infection, or stroke) occurs with lower, but still substantial prevalence, as does cancer pain.

The pathogenic mechanisms that give rise to pain symptoms can be grouped into two main categories:

- those that are components of inflammatory tissue responses (Inflammatory Pain):
- those that result from a neuronal lesion of some form (Neuropathic Pain).

Chronic inflammatory pain consists predominantly of osteoarthritis, chronic low back pain and rheumatoid arthritis. The pain results from acute and on-going injury and/or inflammation. There may be both spontaneous and provoked pain.

There is an underlying pathological hypersensitivity as a result of physiological hyperexcitability and the release of inflammatory mediators which further potentiate this hyperexcitability. CB2 receptors are expressed on inflammatory cells (T cells, B cells, macrophages, mast cells) and mediate immune suppression through inhibition of cellular interaction/ inflammatory mediator release. CB2 receptors may also be expressed on sensory nerve terminals and therefore directly inhibit hyperalgesia.


The role of CB2 in immunomodulation, inflammation, osteoporosis, cardiovascular, renal and other disease conditions is now being examined. In light of the fact that cannabinoids act on receptors capable of modulating different functional effects, and in view of the low homology between CB2 and CB1, the importance of developing a class of drugs selective for the specific receptor sub-type is evident. The natural or synthetic cannabinoids currently available do not fulfil this function because they are active on both receptors.

Based on the foregoing, there is a need for compounds which are capable of selectively modulating the receptor for cannabinoids and, therefore, the pathologies associated with such receptors. Thus, CB2 modulators offer a unique approach toward the pharmacotherapy of immune disorders, inflammation, osteoporosis, renal ischemia and other pathophysiological conditions.

The present invention provides novel pyrimidine derivatives of formula (I) and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions containing these compounds or derivatives, and their use as CB2 receptor modulators, which are useful in the treatment of a variety of disorders.

The present invention further comprises a method for treating disease mediated by CB2 receptors in an animal, including humans, which comprises administering to an animal in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

The invention provides compounds of formula (I):



wherein:


10 Y is phenyl, substituted with one, two or three substituents;

R¹ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, and halosubstituted C₁₋₆ alkyl;

R² is C(R⁷)₂R³;

R³ is an optionally substituted 5- to 6- membered aromatic heterocyclyl group, or group

A:



R⁴ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, and halosubstituted C₁₋₆ alkyl, COCH₃, or SO₂Me;

20 R⁶ is methyl, chloro or CH_xF_n wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3;

Ra can be independently selected from hydrogen, fluoro, chloro or trifluoromethyl;

Rb can be independently be selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, haloC₁₋₆ alkoxy, hydroxy, cyano, halo, sulfonyl, CONH₂, COOH or NHCOOC₁₋₆alkyl;

R⁷ can be independently hydrogen or C₁₋₆ alkyl;

25 and pharmaceutically acceptable derivatives thereof.

with the proviso that the compounds are not

2-(4-*tert*-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide;

2-(4-*tert*-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzyl-methyl-amide;

30 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-methoxy-benzylamide;

2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-bromo-benzylamide.

35

In one particular embodiment Y is substituted by 1 or 2 substituents. If mono-substituted, in one particular embodiment the substituents is in the 3 position; if disubstituted, in one particular embodiment, the substituents are in the 2,4- positions.

Substituents for Y are selected from: C₁₋₆ alkyl, halosubstituted C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy group, cyano group, halo, C₁₋₆alkyl sulfonyl group, or COOH. Furthermore the substituent or substituents can be selected from halosubstituted C₁₋₆ alkoxy, SO₂NR^{8a}R^{8b} wherein R^{8a} and R^{8b} are independently selected from H or C₁₋₆alkyl as defined above, CONH₂, -NHCOC₁₋₆alkyl, or CH₂COOH.

In one particular embodiment Y is substituted by halo, cyano or methoxy.
 In one particular embodiment R¹ is hydrogen or C₁₋₆alkyl, more preferably hydrogen.
 In one particular embodiment R⁴ is C₁₋₆ alkyl or hydrogen, more preferably methyl or hydrogen, even more preferably hydrogen.

In one particular embodiment R² is CH₂R³.
 In one particular embodiment R³ is group A, pyridinyl, or pyrimidinyl, any of which can be optionally substituted.

When R³ is a substituted 5- to 6- membered aromatic heterocyclyl group, the substituent or substituents is/are preferably selected from: C₁₋₆ alkyl, C₁₋₆ alkoxy, haloC₁₋₆ alkoxy, hydroxy, cyano, halo, sulfonyl, CONH₂, or COOH. Additionally the substituent(s) can be selected from methylsulfonyl, NR^{8a}R^{8b} wherein R^{8a} and R^{8b} are independently selected from H or C₁₋₆alkyl, NCOCH₃, (=O) or CONHCH₃. Preferably the halo is fluoro.

In one particular embodiment substituents when R³ is an 5- to 6- membered aromatic heterocyclyl group are halo, methoxy, and cyano.

Alternatively R_b can be independently be selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, haloC₁₋₆ alkoxy, hydroxy, cyano, halo, sulfonyl, CONH₂, or COOH.

In one particular embodiment R_b is selected from hydrogen, halo, methoxy, and cyano.
 In one particular embodiment R⁶ is CH_xF_n, more preferably CF₃.

We have found that at least in the CB2 assay described herein the following compounds are inactive;

2-(4-*tert*-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide;
 2-(4-*tert*-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzyl-methyl-
 amide;
 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-methoxy-
 benzylamide;
 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-bromo-
 benzylamide.

In one particular embodiment the compounds are selective for CB2 over CB1. Preferably the compounds are 100 fold selective i.e. compounds of formula (I) have an EC50 value at the cloned human cannabinoid CB2 receptor of at least 100 times the EC50 values at the cloned human cannabinoid CB1 receptor or have less than 10% efficacy at the CB1 receptor.

The invention is described using the following definitions unless otherwise indicated.

The term "pharmaceutically acceptable derivative" means any pharmaceutically acceptable salt, ester, salt of such ester or solvate of the compounds of formula (I), or any other

compound which upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.

It will be appreciated by those skilled in the art that compounds of formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof at any of the functional groups in the compounds, and that the compounds of formula (I) may be derivatised at more than one position.

It will be appreciated that, for pharmaceutical use, the salts referred to above will be physiologically acceptable salts, but other salts may find use, for example in the preparation of compounds of formula (I) and the physiological acceptable salts thereof. Pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse, J. Pharm. Sci., 1977, 66, 1-19. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropyl amine, tromethamine, and the like. When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.

Preferred examples of pharmaceutically acceptable salts include the ammonium, calcium, magnesium, potassium, and sodium salts, and those formed from maleic, fumaric, benzoic, ascorbic, pamoic, succinic, hydrochloric, sulfuric, bismethylenesalicylic, methanesulfonic, ethanedisulfonic, propionic, tartaric, salicylic, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, cyclohexylsulfamic, phosphoric and nitric acids.

The terms 'halogen or halo' are used to represent fluorine, chlorine, bromine or iodine.

The term 'alkyl' as a group or part of a group means a straight or branched chain alkyl group or combinations thereof, for example a methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, pentyl, hexyl, 1,1-dimethylethyl, or combinations thereof.

The term 'alkoxy' as a group or as part of a group means a straight, branched or cyclic chain alkyl group having an oxygen atom attached to the chain, for example a methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy group, pentoxy, hexyloxy group, cyclopentoxy or cyclohexyloxy group.

The term 'cycloalkyl' means a closed 3- to 7- membered non-aromatic ring, for example cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl

The term 'aryl' means a 5- or 6- membered aromatic ring, for example phenyl, or a 7- to 12-membered bicyclic ring system where at least one of the rings is aromatic, for example naphthyl.


When R³ is an optionally substituted aromatic heterocyclyl group, the ring may contain 1, 2, 3, or 4 hetero atoms. Preferably the hetero atoms are selected from oxygen, nitrogen or sulphur. Examples of 5- membered heterocyclyl groups in this instance include furanyl, dioxalanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, triazinyl, isothiazolyl, isoxazolyl, thienyl, pyrazolyl or tetrazolyl. Examples of 6-membered heterocyclyl groups are pyridinyl, pyrizinyl, pyrimidinyl, pyrazinyl, triazinyl, or tetrazinyl.

Preferred compounds of the present invention can be selected from:

- 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide;
- 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide;
- 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide;
- 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-methoxybenzyl-amide;
- 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzyl-amide;
- 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-cyanobenzyl-amide;
- 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide;
- 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide;
- 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide;
- 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide;
- 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide;
- 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide;
- 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide;
- 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide;
- 2-(2-Methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide;
- 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide;
- 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide;
- 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide;
- 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide;
- 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide;
- 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide;
- 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide;
- 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzyl-amide;

- 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzyl-amide;
2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide;
2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-cyanobenzyl-
5 amide;
2-(4-Cyano-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide;
2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-methyl-pyridin-4-ylmethyl)-amide hydrochloride;
2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-pyridin-4-ylmethyl)-amide;
10 and pharmaceutically acceptable derivatives thereof.

Compounds of formula (I) can be prepared as set forth in the following scheme:



wherein L is a leaving group, for example halo, PG is a protecting group for example methyl, ethyl or benzyl, X is a leaving group, for example halo, OC₁₋₆ alkyl eg O-methyl or O-ethyl or NR^cR^d wherein R^c and R^d are independently selected from C₁₋₆ alkyl eg methyl and R¹, R², R⁴, R⁶ and Y are as defined for compounds of formula (I).

25

It is to be understood that the present invention encompasses all isomers of compounds of formula (I) and their pharmaceutically acceptable derivatives, including all geometric, tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures). Where additional chiral centres are present in compounds of formula (I), the present invention includes within its scope all possible diastereoisomers, including mixtures thereof. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses. The subject invention also includes isotopically-labeled compounds, which are identical to those recited in formulas I and following, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as ^3H , ^{11}C , ^{14}C , ^{18}F , ^{123}I and ^{125}I .

Compounds of the present invention and pharmaceutically acceptable salts of said compounds that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of the present invention. Isotopically-labeled compounds of the present invention, for example those into which radioactive isotopes such as ^3H , ^{14}C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., ^3H , and carbon-14, i.e., ^{14}C , isotopes are particularly preferred for their ease of preparation and detectability. ^{11}C and ^{18}F isotopes are particularly useful in PET (positron emission tomography), and ^{125}I isotopes are particularly useful in SPECT (single photon emission computerized tomography), all useful in brain imaging. Further, substitution with heavier isotopes such as deuterium, i.e., ^2H , can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of formula I and following of this invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

The compounds of formula (I) may be prepared in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated. This invention includes within its scope stoichiometric hydrates or solvates as well as compounds containing variable amounts of water and/or solvent.

The compounds of the invention bind selectively to the CB2 receptor, and are therefore useful in treating CB2 receptor mediated diseases.

In view of their ability to bind to the CB2 receptor, the compounds of the invention may be useful in the treatment of the disorders that follow. Thus, the compounds of formula (I) may be useful as analgesics. For example they may be useful in the treatment of chronic inflammatory pain (e.g. pain associated with rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis) including the property of disease modification and joint structure preservation; musculoskeletal pain; lower back and neck pain; sprains and strains; neuropathic pain; sympathetically maintained pain; myositis; pain associated with cancer and fibromyalgia; pain associated with migraine; pain associated with influenza or other viral infections, such as the common cold; rheumatic fever; pain associated with functional bowel disorders such as non-ulcer

dyspepsia, non-cardiac chest pain and irritable bowel syndrome; pain associated with myocardial ischemia; post operative pain; headache; toothache; and dysmenorrhea.

The compounds of the invention may also be useful disease modification or joint structure preservation in multiple sclerosis, rheumatoid arthritis, osteo-arthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis.

The compounds of the invention may be particularly useful in the treatment of neuropathic pain. Neuropathic pain syndromes can develop following neuronal injury and the resulting pain may persist for months or years, even after the original injury has healed. Neuronal injury may occur in the peripheral nerves, dorsal roots, spinal cord or certain regions in the brain. Neuropathic pain syndromes are traditionally classified according to the disease or event that precipitated them. Neuropathic pain syndromes include: diabetic neuropathy; sciatica; non-specific lower back pain; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; post-herpetic neuralgia; trigeminal neuralgia; and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions. These conditions are difficult to treat and although several drugs are known to have limited efficacy, complete pain control is rarely achieved. The symptoms of neuropathic pain are incredibly heterogeneous and are often described as spontaneous shooting and lancinating pain, or ongoing, burning pain. In addition, there is pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static or thermal allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).

The compounds of formula (I) may also be useful in the treatment of fever.

The compounds of formula (I) may also be useful in the treatment of inflammation, for example in the treatment of skin conditions (e.g. sunburn, burns, eczema, dermatitis, psoriasis); ophthalmic diseases such as glaucoma, retinitis, retinopathies, uveitis and of acute injury to the eye tissue (e.g. conjunctivitis); lung disorders (e.g. asthma, bronchitis, emphysema, allergic rhinitis, respiratory distress syndrome, pigeon fancier's disease, farmer's lung, chronic obstructive pulmonary disease, (COPD); gastrointestinal tract disorders (e.g. aphthous ulcer, Crohn's disease, atopic gastritis, gastritis varioliforme, ulcerative colitis, coeliac disease, regional ileitis, irritable bowel syndrome, inflammatory bowel disease, gastrointestinal reflux disease); organ transplantation; other conditions with an inflammatory component such as vascular disease, migraine, periarteritis nodosa, thyroiditis, aplastic anaemia, Hodgkin's disease, sclerodoma, myasthenia gravis, multiple sclerosis, sarcoidosis, nephrotic syndrome, Bechet's syndrome, polymyositis, gingivitis, myocardial ischemia, pyrexia, systemic lupus erythematosus, tendinitis, bursitis, and Sjogren's syndrome.

The compounds of formula (I) are also useful in the treatment of immunological diseases such as autoimmune diseases, immunological deficiency diseases or organ transplantation. The compounds of formula (I) are also effective in increasing the latency of HIV infection.

The compounds of formula (I) are also useful in the treatment of diseases of abnormal platelet function (e.g. occlusive vascular diseases).

The compounds of formula (I) are also useful for the preparation of a drug with diuretic action.

The compounds of formula (I) are also useful in the treatment of impotence or erectile dysfunction.

5 The compounds of formula (I) are also useful for attenuating the hemodynamic side effects of non-steroidal anti-inflammatory drugs (NSAID's) and cyclooxygenase-2 (COX-2) inhibitors.

10 The compounds of formula (I) are also useful in the treatment of neurodegenerative diseases and neurodegeneration such as dementia, particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntingdon's chorea, Parkinson's disease and Creutzfeldt-Jakob disease, motor neuron disease); vascular dementia (including multi-infarct dementia); as well as dementia associated with intracranial space occupying lesions; trauma; infections and related conditions (including HIV infection); dementia in Parkinson's disease, metabolism; toxins; anoxia and vitamin deficiency; and mild cognitive
15 impairment associated with ageing, particularly Age Associated Memory Impairment. The compounds may also be useful for the treatment of amyotrophic lateral sclerosis (ALS) and neuroinflammation.

20 The compounds of formula (I) are also useful in neuroprotection and in the treatment of neurodegeneration following stroke, cardiac arrest, pulmonary bypass, traumatic brain injury, spinal cord injury or the like.

The compounds of formula (I) are also useful in the treatment of tinnitus.

25 The compounds of formula (I) are also useful in the treatment of psychiatric disease for example schizophrenia, depression (which term is used herein to include bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, seasonal affective disorder, dysthymic disorders with early or late onset and with or without atypical features, neurotic depression and social phobia, depression accompanying dementia for example of the Alzheimer's type, schizoaffective disorder or the depressed type, and depressive disorders resulting from general medical conditions including, but not limited to, myocardial infarction,
30 diabetes, miscarriage or abortion, *etc*), anxiety disorders (including generalised anxiety disorder and social anxiety disorder), panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder, memory disorders, including dementia, amnesic disorders and age-associated memory impairment, disorders of eating behaviours, including anorexia nervosa and bulimia nervosa, sexual dysfunction, sleep disorders (including disturbances
35 of circadian rhythm, dyssomnia, insomnia, sleep apnea and narcolepsy), withdrawal from abuse of drugs such as of cocaine, ethanol, nicotine, benzodiazepines, alcohol, caffeine, phencyclidine (phencyclidine-like compounds), opiates (e.g. cannabis, heroin, morphine), amphetamine or amphetamine-related drugs (e.g. dextroamphetamine, methylamphetamine) or a combination thereof.

40 The compounds of formula (I) are also useful in preventing or reducing dependence on, or preventing or reducing tolerance or reverse tolerance to, a dependence - inducing agent. Examples of dependence inducing agents include opioids (e.g. morphine), CNS depressants (e.g. ethanol), psychostimulants (e.g. cocaine) and nicotine.

The compounds of formula (I) are also useful in the treatment of kidney dysfunction (nephritis, particularly mesangial proliferative glomerulonephritis, nephritic syndrome), liver dysfunction (hepatitis, cirrhosis), gastrointestinal dysfunction (diarrhoea) and colon cancer.

5 It is to be understood that references to treatment includes both treatment of established symptoms and prophylactic treatment unless explicitly stated otherwise.

According to a further aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in human or veterinary medicine.

According to another aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is
10 mediated by the activity of cannabinoid 2 receptors.

According to a further aspect of the invention, we provide a method of treating a human or animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

15 According to a further aspect of the invention we provide a method of treating a human or animal subject suffering from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

20 Preferably the pain is selected from inflammatory pain, visceral pain, cancer pain, neuropathic pain, lower back pain, muscular skeletal, post operative pain, acute pain and migraine. More preferably the inflammatory pain is pain associated with rheumatoid arthritis or osteoarthritis.

According to another aspect of the invention is provided the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a
25 therapeutic agent for the treatment or prevention of a condition such an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

30 In order to use a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the treatment of humans and other mammals it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. Therefore in another aspect of the invention is provided a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof adapted for use in human or
35 veterinary medicine.

As used herein, "modulator" means both antagonist, partial agonist and a full agonist, and inverse agonist. Preferably the present modulators are agonists.

Compounds of formula (I) and their pharmaceutically acceptable derivatives may be administered in a standard manner for the treatment of the indicated diseases, for example orally,
40 parenterally, sub-lingually, dermally, intranasally, transdermally, rectally, via inhalation or via buccal administration.

Compositions of formula (I) and their pharmaceutically acceptable derivatives which are active when given orally can be formulated as syrups, tablets, capsules and lozenges. A syrup

formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavouring or colouring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include
5 magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses,
10 silicates or oils, and are incorporated in a soft gelatin capsule shell.

Typical parenteral compositions consist of a solution or suspension of a compound or derivative in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.

15 Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.

A typical suppository formulation comprises a compound of formula (I) or a pharmaceutically acceptable derivative thereof which is active when administered in this way,
20 with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogs.

Typical dermal and transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.

25 Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose.

Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/Kg, and preferably from 1 mg to 100 mg/Kg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg/Kg, of a compound of formula(I) or a pharmaceutically
30 acceptable derivative thereof calculated as the free acid. Each dosage unit for intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person. A topical formulation contains suitably 0.01 to 5.0% of a compound of formula (I).

The daily dosage regimen for oral administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of a compound of formula(I) or a pharmaceutically acceptable derivative thereof
35 calculated as the free acid. The daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, of a compound of formula (I) or a pharmaceutically acceptable derivative thereof calculated as the free acid. The daily dosage regimen for intranasal administration and oral inhalation is suitably about 10 to about 500 mg/person. The active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity.

40 It may be advantageous to prepare the compounds of the present invention as nanoparticles. This may improve the oral bioavailability of the compounds. For the purposes of the present invention "nanoparticulate" is defined as solid particles with 50% of the particles having a particle size of less than 1µm, more preferably less than 0.75µm

The particle size of the solid particles of compound (I) may be determined by laser diffraction. A suitable machine for determining particle size by laser diffraction is a Lecotrac laser particle size analyser, using an HELOS optical bench fitted with a QUIXEL dispersion unit.

5 Numerous processes for the synthesis of solid particles in nanoparticulate form are known. Typically these processes involve a milling process, preferably a wet milling process in the presence of a surface modifying agent that inhibits aggregation and/or crystal growth of the nanoparticles once created. Alternatively these processes may involve a precipitation process, preferably a process of precipitation in an aqueous medium from a solution of the drug in a non-aqueous solvent.

10 Accordingly, in a further aspect, the present invention provides a process for preparing compound (I) in nanoparticulate form as hereinbefore defined, which process comprises milling or precipitation.

Representative processes for the preparation of solid particles in nanoparticulate form are described in the patents and publications listed below.

15 U.S. Patent No. 4,826,689 to Violanto & Fischer, U. S. Patent No. 5,145,684 to Liversidge et al U.S Patent No. 5,298,262 to Na & Rajagopalan, U.S. Patent No. 5,302,401 Liversidge et al U.S. Patent No. 5,336,507 to Na & Rajagopalan, U.S. Patent No. 5,340,564 to Illig & Sarpotdar U.S. Patent No. 5,346,702 to Na Rajagopalan, U.S. Patent No. 5,352,459 to Hollister et al U.S. Patent No. 5,354,560 to Lovrecich, U.S. Patent No. 5,384,124 to Courteille et al, U.S. Patent
20 No. 5,429,824 to June, U.S. Patent No. 5,503,723 to Ruddy et al, U.S. Patent No. 5,510 118 to Bosch et al, U.S. Patent No. 5,518 to Bruno et al, U.S. Patent No. 5,518,738 to Eickhoff et al, U.S. Patent No. 5,534,270 to De Castro, U.S. Patent No. 5,536,508 to Canal et al, U.S. Patent No. 5,552,160 to Liversidge et al, U.S. Patent No. 5,560,931 to Eickhoff et al, U.S. Patent No. 5,560,932 to Bagchi et al, U.S. Patent No. 5,565,188 to Wong et al, U.S. Patent No. 5,571,536 to
25 Eickhoff et al, U.S. Patent No. 5,573,783 to Desieno & Stetsko, U.S Patent No. 5,580,579 to Ruddy et al, U.S. Patent No 5,585,108 to Ruddy et al, U.S. Patent No. 5,587,143 to Wong, U.S. Patent No. 5,591456 to Franson et al, U.S. Patent No. 5,622,938 to Wong, U.S. Patent No 5,662,883 to Bagchi et al, U.S. Patent No. 5,665,331 to Bagchi et al, U.S Patent No. 5,718,919 to Ruddy et al, U.S. Patent No. 5,747,001 to Wiedmann et al, WO93/25190, WO96/24336, WO
30 97/14407, WO 98/35666, WO 99/65469, WO 00/18374, WO 00/27369, WO 00/30615 and WO 01/41760.

Such processes may be readily adapted for the preparation of compound (I) in nanoparticulate form. Such processes form a further aspect of the invention.

35 The process of the present invention preferably uses a wet milling step carried out in a mill such as a dispersion mill in order to produce a nanoparticulate form of the compound. The present invention may be put into practice using a conventional wet milling technique, such as that described in Lachman *et al.*, The Theory and Practice of Industrial Pharmacy, Chapter 2, "Milling" p.45 (1986).

40 In a further refinement, PCT/EP01/07085 (SmithKline Beecham plc) describes a wet milling procedure using a mill in which at least some of the surfaces are made of nylon (polyamide) comprising one or more internal lubricants, for use in the preparation of solid particles of a drug substance in nanoparticulate form.

In another aspect the present invention provides a process for preparing compounds of the invention in nanoparticulate form comprising wet milling a suspension of compound in a mill having at least one chamber and agitation means, said chamber(s) and/or said agitation means comprising a lubricated nylon, as described in PCT/EP01/07085.

5 The suspension of a compound of the invention for use in the wet milling is typically a liquid suspension of the coarse compound in a liquid medium. By "suspension" is meant that the compound is essentially insoluble in the liquid medium. Representative liquid media include an aqueous medium. Using the process of the present invention the average particle size of coarse compound of the invention may be up to 1mm in diameter. This advantageously avoids the need to pre-process the
10 compound.

In a further aspect of the invention the aqueous medium to be subjected to the milling comprises compound (I) present in from about 1% to about 40% w/w, preferably from about 10% to about 30% w/w, more preferably about 20% w/w.

The aqueous medium may further comprise one or more pharmaceutically acceptable water-
15 soluble carriers which are suitable for steric stabilisation and the subsequent processing of compound (I) after milling to a pharmaceutical composition, e.g. by spray drying. Pharmaceutically acceptable excipients most suitable for steric stabilisation and spray-drying are surfactants such as poloxamers, sodium lauryl sulphate and polysorbates etc; stabilisers such as celluloses e.g. hydroxypropylmethyl cellulose; and carriers such as carbohydrates e.g. mannitol.

20 In a further aspect of the invention the aqueous medium to be subjected to the milling may further comprise hydroxypropylmethyl cellulose (HPMC) present in from about 0.1 to about 10% w/w.

The process of the present invention may comprise the subsequent step of drying compound of the invention to yield a powder.

25 Accordingly, in a further aspect, the present invention provides a process for preparing a pharmaceutical composition contain a compound of the present invention which process comprises producing compound of formula (I) in nanoparticulate form optionally followed by drying to yield a powder.

A further aspect of the invention is a pharmaceutical composition comprising a
30 compound of formula (I) or a pharmaceutically acceptable derivative thereof in which the compound of formula (I) or a pharmaceutically acceptable derivative thereof is present in solid particles in nanoparticulate form, in admixture with one or more pharmaceutically acceptable carriers or excipients.

By "drying" is meant the removal of any water or other liquid vehicle used during the
35 process to keep compound of formula (I) in liquid suspension or solution. This drying step may be any process for drying known in the art, including freeze drying, spray granulation or spray drying. Of these methods spray drying is particularly preferred. All of these techniques are well known in the art. Spray drying/fluid bed granulation of milled compositions is carried out most suitably using a spray dryer such as a Mobile Minor Spray Dryer [Niro, Denmark], or a fluid bed
40 drier, such as those manufactured by Glatt, Germany.

In a further aspect the invention provides a pharmaceutical composition as hereinbefore defined, in the form of a dried powder, obtainable by wet milling solid particles of compound of formula (I) followed by spray-drying the resultant suspension.

Preferably, the pharmaceutical composition as hereinbefore defined, further comprises HPMC present in less than 15% w/w, preferably in the range 0.1 to 10% w/w.

The CB₂ receptor compounds for use in the instant invention may be used in combination with other therapeutic agents, for example COX-2 inhibitors, such as celecoxib, deracoxib, rofecoxib, valdecoxib, parecoxib or COX-189; 5-lipoxygenase inhibitors; NSAID's, such as aspirin, diclofenac, indomethacin, nabumetone or ibuprofen; leukotriene receptor antagonists; DMARD's such as methotrexate; adenosine A1 receptor agonists; sodium channel blockers, such as lamotrigine; NMDA receptor modulators, such as glycine receptor antagonists; gabapentin and related compounds; tricyclic antidepressants such as amitriptyline; neurone stabilising antiepileptic drugs; mono-aminergic uptake inhibitors such as venlafaxine; opioid analgesics; local anaesthetics; 5HT₁ agonists, such as triptans, for example sumatriptan, naratriptan, zolmitriptan, eletriptan, frovatriptan, almotriptan or rizatriptan; EP₁ receptor ligands, EP₄ receptor ligands; EP₂ receptor ligands; EP₃ receptor ligands; EP₄ antagonists; EP₂ antagonists and EP₃ antagonists; bradykinin receptor ligands and vanilloid receptor ligand. antirheumatoid arthritis drugs, for example anti TNF drugs e.g. enbrel, remicade, anti-IL-1 drugs, or DMARDS e.g. leflunamide. When the compounds are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.

Additional COX-2 inhibitors are disclosed in US Patent Nos. 5,474,995 US5,633,272; US5,466,823, US6,310,099 and US6,291,523; and in WO 96/25405, WO 97/38986, WO 98/03484, WO 97/14691, WO99/12930, WO00/26216, WO00/52008, WO00/38311, WO01/58881 and WO02/18374.

The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent or agents.

Suitable 5HT₃ antagonists which may be used in combination of the compound of the inventions include for example ondansetron, granisetron, metoclopramide.

Suitable serotonin agonists which may be used in combination with the compound of the invention include sumatriptan, rauwolscine, yohimbine, metoclopramide.

Suitable SSRIs which may be used in combination with the compound of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline, zimeldine.

Suitable SNRIs which may be used in combination with the compound of the invention include venlafaxine and reboxetine.

Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptyline, chlomipramine and nortriptyline.

Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and amineptine.

It will be appreciated that the compounds of any of the above combinations or compositions may be administered simultaneously (either in the same or different pharmaceutical formulations), separately or sequentially.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further

aspect of the invention. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

When a compound of formula (I) or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the same disease state the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

Determination of cannabinoid CB1 Receptor Agonist Activity

The cannabinoid CB1 receptor agonist activity of the compounds of formula (I) was determined in accordance with the following experimental method.

Experimental Method

Yeast (*Saccharomyces cerevisiae*) cells expressing the human cannabinoid CB1 receptor were generated by integration of an expression cassette into the *ura3* chromosomal locus of yeast strain MMY23. This cassette consisted of DNA sequence encoding the human CB1 receptor flanked by the yeast GPD promoter to the 5' end of CB1 and a yeast transcriptional terminator sequence to the 3' end of CB1. MMY23 expresses a yeast/mammalian chimeric G-protein alpha subunit in which the C-terminal 5 amino acids of Gpa1 are replaced with the C-terminal 5 amino acids of human Gαi3 (as described in Brown *et al.* (2000), *Yeast* 16:11-22). Cells were grown at 30°C in liquid Synthetic Complete (SC) yeast media (Guthrie and Fink (1991), *Methods in Enzymology*, Vol. 194) lacking uracil, tryptophan, adenine and leucine to late logarithmic phase (approximately 6 OD₆₀₀/ml).

Agonists were prepared as 10 mM stocks in DMSO. EC₅₀ values (the concentration required to produce 50% maximal response) were estimated using dilutions of between 3- and 5-fold (BiomekFX, Beckman) into DMSO. Agonist solutions in DMSO (1% final assay volume) were transferred into black, clear bottom, microtitre plates from NUNC (96- or 384-well). Cells were suspended at a density of 0.2 OD₆₀₀/ml in SC media lacking histidine, uracil, tryptophan, adenine and leucine and supplemented with 10mM 3-aminotriazole, 0.1M sodium phosphate pH 7.0, and 20μM fluorescein di-β-D-glucopyranoside (FDGlu). This mixture (50ul per well for 384-well plates, 200ul per well for 96-well plates) was added to agonist in the assay plates (Multidrop 384, Labsystems). After incubation at 30°C for 24 hours, fluorescence resulting from degradation of FDGlu to fluorescein due to exoglucanase, an endogenous yeast enzyme produced during agonist-stimulated cell growth, was determined using a Spectrofluor microtitre plate reader (Tecan; excitation wavelength: 485nm; emission wavelength: 535nm). Fluorescence was plotted against compound concentration and iteratively curve fitted using a four parameter fit to generate a concentration effect value. Efficacy (E_{max}) was calculated from the equation

$$E_{\max} = \frac{\text{Max}_{[\text{compound X}]} - \text{Min}_{[\text{compound X}]}}{\text{Max}_{[\text{HU210}]} - \text{Min}_{[\text{HU210}]}} \times 100\%$$

where Max_[compound X] and Min_[compound X] are the fitted maximum and minimum respectively from the concentration effect curve for compound X, and Max_[HU210] and Min_[HU210] are the fitted maximum and minimum respectively from the concentration effect curve for (6aR,10aR)-3-(1,1'-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol (HU210; available from Tocris). Equieffective molar ratio (EMR) values were calculated from the equation

$$EMR = EC_{50 \text{ [compound X]}} / EC_{50 \text{ [HU210]}}$$

Where $EC_{50 \text{ [compound X]}}$ is the EC_{50} of compound X and $EC_{50 \text{ [HU210]}}$ is the EC_{50} of HU210.

Compounds of the Examples tested according to this method had EC_{50} values $>2000\text{nM}$ and/or efficacy values of $<50\%$ at the cloned human cannabinoid CB1 receptor.

5

Determination of cannabinoid CB2 Receptor Agonist Activity

The cannabinoid CB2 receptor agonist activity of the compounds of formula (I) was determined in accordance with the following experimental method.

10 Experimental Method

Yeast (*Saccharomyces cerevisiae*) cells expressing the human cannabinoid CB2 receptor were generated by integration of an expression cassette into the *ura3* chromosomal locus of yeast strain MMY23. This cassette consisted of DNA sequence encoding the human CB2 receptor flanked by the yeast GPD promoter to the 5' end of CB2 and a yeast transcriptional terminator sequence to the 3' end of CB2. MMY23 expresses a yeast/mammalian chimeric G-protein alpha subunit in which the C-terminal 5 amino acids of Gpa1 are replaced with the C-terminal 5 amino acids of human Gai3 (as described in Brown *et al.* (2000), *Yeast* 16:11-22). Cells were grown at 30°C in liquid Synthetic Complete (SC) yeast media (Guthrie and Fink (1991), Methods in Enzymology, Vol. 194) lacking uracil, tryptophan, adenine and leucine to late logarithmic phase (approximately 6 OD₆₀₀/ml).

Agonists were prepared as 10 mM stocks in DMSO. EC_{50} values (the concentration required to produce 50% maximal response) were estimated using dilutions of between 3- and 5-fold (BiomekFX, Beckman) into DMSO. Agonist solutions in DMSO (1% final assay volume) were transferred into black, clear bottom, microtitre plates from NUNC (96- or 384-well). Cells were suspended at a density of 0.2 OD₆₀₀/ml in SC media lacking histidine, uracil, tryptophan, adenine and leucine and supplemented with 10mM 3-aminotriazole, 0.1M sodium phosphate pH 7.0, and 20M fluorescein di-β-D-glucopyranoside (FDGlu). This mixture (50ul per well for 384-well plates, 200ul per well for 96-well plates) was added to agonist in the assay plates (Multidrop 384, Labsystems). After incubation at 30°C for 24 hours, fluorescence resulting from degradation of FDGlu to fluorescein due to exoglucanase, an endogenous yeast enzyme produced during agonist-stimulated cell growth, was determined using a Spectrofluor microtitre plate reader (Tecan; excitation wavelength: 485nm; emission wavelength: 535nm). Fluorescence was plotted against compound concentration and iteratively curve fitted using a four parameter fit to generate a concentration effect value. Efficacy (E_{max}) was calculated from the equation

$$E_{\text{max}} = \frac{\text{Max}_{[\text{compound X}]} - \text{Min}_{[\text{compound X}]}}{\text{Max}_{[\text{HU210}]} - \text{Min}_{[\text{HU210}]}} \times 100\%$$

where $\text{Max}_{[\text{compound X}]}$ and $\text{Min}_{[\text{compound X}]}$ are the fitted maximum and minimum respectively from the concentration effect curve for compound X, and $\text{Max}_{[\text{HU210}]}$ and $\text{Min}_{[\text{HU210}]}$ are the fitted maximum and minimum respectively from the concentration effect curve for (6aR,10aR)-3-(1,1'-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol (HU210; available from Tocris). Equieffective molar ratio (EMR) values were calculated from the equation

$$EMR = EC_{50 \text{ [compound X]}} / EC_{50 \text{ [HU210]}}$$

Where $EC_{50 \text{ [compound X]}}$ is the EC_{50} of compound X and $EC_{50 \text{ [HU210]}}$ is the EC_{50} of HU210.

Compounds of Examples 1 to 29 and 79 to 104 tested according to this method had EC₅₀ values 20 to 1000nM and efficacy values of >50% at the cloned human cannabinoid CB2 receptor.

5 Compounds of Examples 30 to 42 tested according to this method had EC₅₀ values > 1000nM or efficacy values of <50% at the cloned human cannabinoid CB2 receptor.

Compounds of Examples 43 to 78 and 105 to 114 tested according to this method had EC₅₀ values > 1000nM and efficacy values of <50% at the cloned human cannabinoid CB2 receptor.

10 The following examples are illustrative, but not limiting of the embodiments of the present invention.

All NMR experimental data was recorded at 400MHz.

Conditions, Hardware, and Software used for Mass-directed Autopurification

15

Hardware

Waters 600 gradient pump, Waters 2700 sample manager, Waters Reagent Manager, Micromass ZMD mass spectrometer, Gilson 202 - fraction collector, Gilson Aspec - waste collector.

Software

Micromass Masslynx version 3.5

Column

25 The column used is typically a Supelco ABZ+ column whose dimensions are 10mm internal diameter by 100mm in length. The stationary phase particle size is 5µm.

Solvents

A. Aqueous solvent = Water + 0.1% Formic Acid

B. Organic solvent = MeCN: Water 95:5 +0.05% Formic Acid

30 Make up solvent = MeOH: Water 80:20 +50mMol Ammonium Acetate

Needle rinse solvent = MeOH: Water: DMSO 80:10:10

Methods

Five methods are used depending on the analytical retention time of the compound of interest.

35 They all have a flow rate of 20ml/min and a 15-minute runtime, which comprises of a 10-minute gradient followed by a 5-minute column flush and re-equilibration step.

Method 1 MDP 1.5-2.2 = 0-30%B

Method 2 MDP 2.0-2.8 = 5-30% B


40 Method 3 MDP 2.5-3.0 = 15-55%B

Method 4 MDP 2.8-4.0 = 30-80% B


Method 5 MDP 3.8-5.5 = 50-90% B

Example 1: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide


- (a). To a solution of benzyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.50 g, ex
 5 Maybridge) in 1,4-dioxan (5 ml) was added 3-chloroaniline (0.85 ml) and the solution stirred at room temperature for 15 h. 1,4-Dioxan was removed under reduced pressure and ethyl acetate (15 ml) added. The solution was washed sequentially with 2N hydrochloric acid (10 ml) and water (3 x 10 ml), dried (MgSO₄), evaporated and triturated with hexane to afford benzyl 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (524 mg).
 10 NMR (400MHz, DMSO-d₆) δ 5.35 (2H, s), 7.14 (1H, d), 7.35-7.45 (6H, m), 7.68 (1H, m), 7.98 (1H, s), 9.13 (1H, s), 10.95 (1H, s).
 LC/MS, t = 3.70 min, [MH⁺] 408 and 410.



- (b). To a solution of benzyl 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate
 15 (0.50 g) in ethanol (15 ml) was added a solution of potassium hydroxide (205 mg) in ethanol (10 ml) and the solution stirred at reflux for 15 h. Ethanol was removed under reduced pressure and water (15 ml) added. The solution was washed with ether and concentrated hydrochloric acid added to adjust the acidity to pH 1. The precipitated solid was filtered, washed with water and dried in vacuo at 50°C to afford 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (366 mg,).
 20 NMR (400MHz, DMSO-d₆) δ 7.49 (1H, d), 7.71 (1H, t), 7.98 (1H, d), 8.33 (1H, s), 9.42 (1H, s), 11.15 (1H, s), 14.0 (1H, br s).
 LC/MS, t = 3.44 min, [MH⁺] 318 and 320.



- (c). To a solution of 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) in dimethylformamide (2 ml) was added successively N-ethylmorpholine (42 μ l), benzylamine (15 μ l), 1-hydroxybenzotriazole hydrate (23 mg) and 1-(3-dimethylamino-propyl)-3-ethylcarbodiimide hydrochloride (25 mg). The solution was stirred for 3 h and allowed to stand overnight. Dimethylformamide was removed under reduced pressure and ethyl acetate (5 ml)
 30 added. The solution was washed sequentially with 5% sodium bicarbonate solution (2.5 ml), water (2.5 ml), 5% citric acid solution (2.5 ml) and brine (2 x 2.5 ml), dried (MgSO₄) and evaporated to afford the title compound (45 mg).
 NMR (400MHz, DMSO-d₆) δ 4.47 (2H, d), 7.10 (1H, d), 7.25 (1H, m), 7.36 (5H, m), 7.69 (1H, d), 7.98 (1H, s), 8.89 (1H, s), 9.12 (1H, t), 10.65 (1H, s).
 35 LC/MS, t = 3.23 min, [MH⁺] 407 and 409.



Example 2: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide




5

In a manner similar to Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and 4-(aminomethyl)pyridine (13.5 μ l) afforded the title compound (32 mg).

10 NMR (400MHz, DMSO-d₆) δ 4.48 (2H, d), 7.10 (1H, d), 7.37 (3H, m), 7.69 (1H, d), 7.98 (1H, s), 8.55 (2H, d), 8.97 (1H, s), 9.26 (1H, t), 10.65 (1H, s).

LC/MS, t = 2.90 min, [MH⁺] 408 and 410.

Example 3: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide




15

In a manner similar to Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and N-methylbenzylamine (17 μ l) afforded the title compound (46 mg).

20 NMR (400MHz, DMSO-d₆) Rotamers in 65:35 ratio δ 2.88 (1.95H, s), 2.98 (1.05H, s), 4.58 (0.7H, br s), 4.75 (1.3H, br s), 7.17 (1H, t), 7.30 (1H, d), 7.35-7.5 (5H, m), 7.72 (1H, t), 8.00 (0.35H, t), 8.06 (0.65H, t), 8.89 (0.35H, s), 8.95 (0.65H, s), 10.65 (0.35H, s), 10.7 (0.65H, s).

LC/MS, t = 3.35 min, [MH⁺] 421 and 423.


Example 4: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-methoxybenzyl-amide



25 In a manner similar to Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and 4-methoxybenzylamine (17 μ l) afforded the title compound (18 mg).


NMR (400MHz, DMSO-d₆) δ 3.75 (3H, s), 4.40 (2H, d), 6.94 (2H, d), 7.10 (1H, d), 7.28 (2H, d), 7.38 (1H, t), 7.69 (1H, d), 7.98 (1H, s), 8.88 (1H, s), 9.08 (1H, t), 10.65 (1H, s).
LC/MS, $t \approx 3.57$ min, $[MH^+]$ 437 and 439.

5 **Example 5: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzyl-amide**



- 10 In a manner similar to Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and 4-fluorobenzylamine hydrochloride (21 mg) afforded the title compound (35 mg).
NMR (400MHz, DMSO-d₆) δ 4.45 (2H, d), 7.10 (1H, d), 7.18 (2H, t), 7.35-7.45 (3H, m), 7.68 (1H, d), 7.97 (1H, s), 8.89 (1H, s), 9.14 (1H, t), 10.65 (1H, s).
15 LC/MS, $t = 3.68$ min, $[MH^+]$ 425 and 427.

Example 6: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-cyanobenzyl-amide




- 20 In a manner similar to Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and 4-cyanobenzylamine (17.5 mg) afforded the title compound (13 mg).
NMR (400MHz, DMSO-d₆) δ 4.94 (2H, d), 7.49 (1H, d), 7.68 (1H, t), 7.95 (2H, d), 8.06 (1H, d), 8.23 (2H, d), 8.38 (1H, s), 9.32 (1H, s), 9.64 (1H, t), 11.05 (1H, s).
LC/MS, $t = 3.56$ min, $[MH^+]$ 432 and 434.

25

Example 7: 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide


- (a). To a solution of methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.40 g, ex
30 Maybridge) in 1,4-dioxan (5 ml) was added 2,3-dichloroaniline (1.27 g) and the solution stirred at reflux temperature for 24 h. 1,4-Dioxan was removed under reduced pressure and ethyl acetate (15 ml) added. The solution was washed sequentially with 2N hydrochloric acid (10 ml) and water (3 x 10 ml), dried (MgSO₄), evaporated and triturated with hexane to afford methyl 2-(2,3-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylate (176 mg,).
35 NMR (400MHz, CDCl₃) δ 3.97 (3H, s), 7.25 (2H, m), 8.15 (1H, s), 8.48 (1H, d), 9.07 (1H, s).
LC/MS, $t = 3.68$ min, $[MH^+]$ 366 and 368.



- (b). In a manner similar to Example 1(b) methyl 2-(2,3-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.18 g) afforded 2-(2,3-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.13 g).


NMR (400MHz, DMSO-d₆) δ 7.40 (1H, t), 7.56 (2H, d), 8.96 (1H, s), 10.45 (1H, s), 13.6 (1H, s).

LC/MS, t = 4.06 min, [MH⁺-CO₂] 306 and 308.



- (c). In a manner similar to Example 1(c) 2-(2,3-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (39 mg) and N-methylbenzylamine (21.5 μ l) afforded the title compound (50 mg).

NMR (400MHz, CDCl₃) Rotamers in 65:35 ratio δ 2.79 (1.95H, s), 3.08 (1.05H, s), 4.42 (0.7H, br s), 4.78 (1.3H, br s), 7.14 (1H, d), 7.2-7.3 (2H, m), 7.3-7.45 (4H, m), 7.96 (0.35H, s), 8.01 (0.65H, s), 8.40 (0.35H, d), 8.45 (0.65H, d), 8.55 (0.35H, s), 8.59 (0.65H, s).
LC/MS, t = 3.74 min, [MH⁺] 455 and 457.




Example 8: 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide

- (a). In a manner similar to Example 7(a) methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 2,4-dichloroaniline (1.7 g) afforded methyl 2-(2,4-dichlorophenyl-amino)-4-trifluoromethylpyrimidine-5-carboxylate (214 mg).

NMR (400MHz, CDCl₃) δ 3.95 (3H, s), 7.33 (1H, d), 7.46 (1H, d), 7.99 (1H, s), 8.48 (1H, d), 9.06 (1H, s).


LC/MS, t = 3.74 min, [MH⁺] 366 and 368.



- (b). In a manner similar to Example 1(b) methyl 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.21 g) afforded 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.18 g).

NMR (400MHz, DMSO-d₆) δ 7.47 (1H, d), 7.60 (1H, d), 7.75 (1H, s), 8.96 (1H, s), 10.3 (1H, s), 13.6 (1H, s).

LC/MS, t = 4.17 min, [MH⁺-CO₂] 306 and 308.




10

- (c). In a manner similar to Example 1(c) 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (39 mg) and benzylamine (18 μ l) afforded the title compound (41 mg).

NMR (400MHz, CDCl₃) δ 4.64 (2H, d), 6.08 (1H, br s), 7.25-7.4 (5H, m), 7.44 (1H, d), 7.90 (1H, s), 8.43 (1H, d), 8.74 (1H, s).

15

LC/MS, t = 3.69 min, [MH⁺] 441 and 443.



Example 9: 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide


20

- (a). In a manner similar to Example 7(a) methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 3,4-dichloroaniline (1.7 g) afforded methyl 2-(3,4-dichlorophenyl-amino)-4-trifluoromethylpyrimidine-5-carboxylate (591 mg).

NMR (400MHz, CDCl₃) δ 3.96 (3H, s), 7.45 (2H, m), 7.57 (1H, s), 7.98 (1H, s), 9.07 (1H, s).

25


LC/MS, t = 3.87 min, [MH⁺] 366 and 368.



- (b). In a manner similar to Example 1(b) methyl 2-(3,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.59 g) afforded 2-(3,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.51 g).

NMR (400MHz, DMSO-d₆) δ 7.65 (1H, d), 7.72 (1H, d of d), 8.19 (1H, s), 9.12 (1H, s), 10.95 (1H, s), 13.7 (1H, s).

LC/MS, t = 4.49 min, [MH⁺-CO₂] 306 and 308.




10

- (c). In a manner similar to Example 1(c) 2-(3,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (39 mg) and benzylamine (18 μ l) afforded the title compound (51 mg).

NMR (400MHz, CDCl₃) δ 4.65 (2H, d), 6.10 (1H, br s), 7.3-7.4 (5H, m), 7.42 (1H, s), 7.45 (1H, s), 7.94 (1H, s), 8.78 (1H, s).

15

LC/MS, t = 3.80 min, [MH⁺] 441 and 443.



Example 10: 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid


20

N-benzyl-N-methylamide


- (a). In a manner similar to Example 7(a) methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 2,6-dichloroaniline (1.7 g) in 1,4-dioxan (5 ml) was stirred at reflux temperature for 7 days to afford methyl 2-(2,6-dichlorophenyl-amino)-4-trifluoromethylpyrimidine-5-carboxylate (136 mg).

25


LC/MS, t = 3.43 min, [MH⁺] 366 and 368.



- (b). In a manner similar to Example 1(b) methyl 2-(2,6-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (135 mg) afforded 2-(2,6-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (114 mg).
- 5 NMR (400MHz, DMSO-d₆) δ 7.41 (1H, t), 7.60 (2H, d), 8.92 (1H, br s), 10.5 (1H, s), 13.6 (1H, br s).



- (c). In a manner similar to Example 1(c) 2-(2,6-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (40 mg) and N-methylbenzylamine (18 μ l) afforded the title compound (49 mg).
- 10 NMR (400MHz, DMSO-d₆) Rotamers in 65:35 ratio δ 2.83 (1.95H, s), 2.98 (1.05H, s), 4.51 (0.7H, s), 4.74 (1.3H, br s), 7.26 (1H, d), 7.3-7.5 (5H, m), 7.65 (2H, t), 8.69 (0.35H, br s), 8.78 (0.65H, br s), 10.3 (1H, s).
- 15 LC/MS, t = 3.51 min, [MH⁺] 455 and 457.




Example 11: 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide


20

- (a). In a manner similar to Example 7(a) methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 3,5-dichloroaniline (1.7 g) afforded methyl 2-(3,5-dichlorophenyl-amino)-4-trifluoromethylpyrimidine-5-carboxylate (0.76 g).

LC/MS, $t = 3.96$ min, $[MH^+]$ 366 and 368.




- 5 (b). In a manner similar to Example 1(b) methyl 2-(3,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.76g) afforded 2-(3,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.65 g).
NMR (400MHz, DMSO-d₆) δ 7.28 (1H, s), 7.90 (2H, s), 9.14 (1H, s), 10.95 (1H, s), 13.75 (1H, br s).




10

- (c). In a manner similar to Example 1(c) 2-(3,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and benzylamine (13 μ l) afforded the title compound (29 mg).
15 NMR (400MHz, DMSO-d₆) δ 4.48 (2H, d), 7.25 (2H, m), 7.38 (4H, m), 7.89 (2H, s), 8.95 (1H, s), 9.16 (1H, t), 10.8 (1H, s).
LC/MS, $t = 3.87$ min, $[MH^+]$ 441 and 443.




20 **Example 12: 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide**


- (a). In a manner similar to Example 1(a) methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 3-fluoroaniline (1.16 g) afforded methyl 2-(3-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.65 g).
25 NMR (400MHz, DMSO-d₆) δ 3.88 (3H, s), 6.95 (1H, t of d), 7.40 (1H, q), 7.54 (1H, d), 7.79 (1H, d of t), 9.12 (1H, s), 10.95 (1H, s).
LC/MS, $t = 3.50$ min, $[MH^+]$ 316.



- (b). In a manner similar to Example 1(b) methyl 2-(3-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.65g) afforded 2-(3-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.54 g).
 NMR (400MHz, DMSO-d₆) δ 6.90 (1H, t of d), 7.39 (1H, q), 7.55 (1H, d), 7.80 (1H, d of t), 9.10 (1H, s), 10.85 (1H, s), 13.7 (1H, br s).




- (c). In a manner similar to Example 1(c) 2-(3-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and benzylamine (15 μ l) afforded the title compound (35 mg).
 NMR (400MHz, DMSO-d₆) δ 4.46 (2H, d), 6.87 (1H, t of d), 7.28 (1H, m), 7.35 (5H, m), 7.52 (1H, d), 7.78 (1H, d of t), 8.89 (1H, s), 9.15 (1H, t), 10.65 (1H, s).
 LC/MS, $t = 3.47$ min, $[MH^+]$ 391.




Example 13: 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide

- (a). In a manner similar to Example 1(a) methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 3-bromoaniline (1.79 g) afforded methyl 2-(3-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.68 g).
 NMR (400MHz, DMSO-d₆) δ 3.88 (3H, s), 7.30 (2H, m), 7.72 (1H, d), 8.12 (1H, s), 9.11 (1H, s), 10.90 (1H, s).
 LC/MS, $t = 3.70$ min, $[MH^+]$ 376 and 378.



- (b). In a manner similar to Example 1(b) methyl 2-(3-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.68 g) afforded 2-(3-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.57 g).


NMR (400MHz, DMSO-d₆) δ 7.30 (2H, m), 7.73 (1H, d), 8.15 (1H, s), 9.09 (1H, s), 10.80 (1H, s), 13.65 (1H, br s).




- (c). In a manner similar to Example 1(c) 2-(3-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and benzylamine (13 μ l) afforded the title compound (23 mg).

NMR (400MHz, DMSO-d₆) δ 4.47 (2H, d), 7.2-7.4 (7H, m), 7.71 (1H, d), 8.11 (1H, s), 8.89 (1H, s), 9.15 (1H, t), 10.65 (1H, s).

LC/MS, $t = 3.64$ min, $[MH^+]$ 451 and 453.



Example 14: 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide



- In a manner similar to Example 1(c) 2-(3-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and N-methylbenzylamine (15 μ l) afforded the title compound (45 mg).
- NMR (400MHz, DMSO-d₆) Rotamers in 65:35 ratio δ 2.89 (1.95H, s), 2.98 (1.05H, s), 4.58 (0.7H, br s), 4.76 (1.3H, br s), 7.28 (1H, d), 7.25-7.5 (6H, m), 7.76 (1H, t), 8.13 (0.35H, t), 8.19 (0.65H, t), 8.88 (0.35H, s), 8.95 (0.65H, s), 10.6 (0.35H, s), 10.65 (0.65H, s).

LC/MS, $t = 3.72$ min, $[MH^+]$ 465 and 467.

Example 15: 2-(2-Methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-amide


5

(a). In a manner similar to Example 1(a) benzyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 2-methoxyaniline (0.97 g) afforded benzyl 2-(2-methoxyphenyl-amino)-4-trifluoromethyl-pyrimidine-5-carboxylate (0.57 g).

NMR (400MHz, $CDCl_3$) δ 3.93 (3H, s), 5.38 (2H, s), 6.93 (1H, d), 7.04 (1H, t), 7.09 (1H, t),

10 7.35-7.45 (4H, m), 8.26 (1H, br s), 8.49 (1H, br d), 9.06 (1H, s).


LC/MS, $t = 3.42$ min, $[MH^+]$ 404.



(b). In a manner similar to Example 1(b) benzyl 2-(2-methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.55 g) afforded 2-(2-methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.38 g).

NMR (400MHz, $DMSO-d_6$) δ 3.80 (3H, s), 6.98 (1H, t), 7.10 (1H, d), 7.22 (1H, t), 7.62 (1H, d), 8.94 (1H, s), 9.62 (1H, s), 13.5 (1H, s).

LC/MS, $t = 3.03$ min, $[MH^+]$ 314.




20


(c). In a manner similar to Example 1(c) 2-(2-methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and benzylamine (18 μ l) afforded, after silica gel chromatography using 1:1 ethyl acetate:isohexane, the title compound (38 mg).

25 NMR (400MHz, $CDCl_3$) δ 3.93 (3H, s), 4.65 (2H, d), 6.09 (1H, br s), 6.90 (1H, d), 7.05 (2H, m), 7.35 (5H, m), 8.25 (1H, s), 8.47 (1H, d), 8.75 (1H, s).

LC/MS, $t = 3.14$ min, $[MH^+]$ 403.




Example 16: 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide




- 5 In a manner similar to Example 1(c) 2-(2,3-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (24 mg) and 4-(aminomethyl)pyridine (10 μ l) afforded the title compound (19 mg).
- NMR (400MHz, DMSO-d₆) δ 4.48 (2H, d), 7.34 (2H, d), 7.41 (1H, t), 7.55 (2H, m), 8.52 (2H, d), 8.81 (1H, s), 9.23 (1H, t), 10.20 (1H, s).
- 10 LC/MS, t = 2.95 min, [MH⁺] 442 and 444.

Example 17: 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide



- 15 In a manner similar to Example 1(c) 2-(2,4-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (30 mg) and 4-(aminomethyl)pyridine (10.5 μ l) afforded the title compound (24 mg).
- NMR (400MHz, DMSO-d₆) δ 4.48 (2H, d), 7.33 (2H, d), 7.48 (1H, d of d), 7.60 (1H, d), 7.75 (1H, s), 8.52 (2H, d), 8.80 (1H, s), 9.22 (1H, t), 10.10 (1H, s).
- 20 LC/MS, t = 3.00 min, [MH⁺] 442 and 444.

Example 18: 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide



25

In a manner similar to Example 1(c) 2-(3,4-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (30 mg) and 4-(aminomethyl)pyridine (10.5 μ l) afforded the title compound (32 mg).


NMR (400MHz, DMSO-d₆) δ 4.50 (2H, d), 7.36 (2H, d), 7.62 (1H, d), 7.70 (1H, d of d), 8.18 (1H, s), 8.55 (2H, d), 8.99 (1H, s), 9.27 (1H, t), 10.75 (1H, s).

LC/MS, t = 3.17 min, [MH⁺] 442 and 444.

Example 19: 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide


(a). In a manner similar to Example 8(a) methyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 2,5-dichloroaniline (1.7 g) afforded methyl 2-(2,5-dichlorophenyl-amino)-4-trifluoromethylpyrimidine-5-carboxylate (681 mg).

LC/MS, t = 3.73 min, [MH⁺] 366 and 368.



(b). In a manner similar to Example 1(b) methyl 2-(2,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.68 g) afforded 2-(2,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (0.48 g).


NMR (400MHz, DMSO-d₆) δ 7.36 (1H, d of d), 7.60 (1H, d), 7.76 (1H, d), 8.99 (1H, s), 10.3 (1H, s), 13.6 (1H, br s).




In a manner similar to Example 1(c) 2-(2,5-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and 4-(aminomethyl)pyridine (17 μ l) afforded the title compound (35 mg).

NMR (400MHz, DMSO-d₆) δ 4.47 (2H, d), 7.33 (3H, m), 7.60 (1H, d), 7.73 (1H, d), 8.54 (2H, d), 8.84 (1H, s), 9.21 (1H, t), 10.10 (1H, s).

LC/MS, t = 2.96 min, [MH⁺] 442 and 444.



Example 20: 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide




5

In a manner similar to Example 1(c) 2-(3-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and 4-(aminomethyl)pyridine (12 μ l) afforded the title compound (28 mg).

10 NMR (400MHz, DMSO-d₆) δ 4.51 (2H, d), 6.88 (1H, t of d), 7.4 (3H, m), 7.55 (1H, d), 7.80 (1H, d of t), 8.56 (2H, d), 8.96 (1H, s), 9.26 (1H, t), 10.70 (1H, s).
LC/MS, t = 2.65 min, [MH⁺] 392.

Example 21: 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide

15




20 In a manner similar to Example 1(c) 2-(3-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and 4-(aminomethyl)pyridine (12 μ l) afforded the title compound (29 mg).

NMR (400MHz, DMSO-d₆) δ 4.48 (2H, d), 7.24 (1H, d), 7.34 (1H, t), 7.38 (2H, d), 7.73 (1H, d), 8.13 (1H, s), 8.56 (2H, d), 8.98 (1H, s), 9.26 (1H, t), 10.65 (1H, s).
LC/MS, t = 2.91 min, [MH⁺] 452 and 454.

Example 22: 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)amide

25




In a manner similar to Example 1(c) 2-(3-(3,5-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and 4-(aminomethyl)pyridine (17 μ l) afforded the title compound (39 mg).

- 5 NMR (400MHz, DMSO- d_6) δ 4.48 (2H, d), 7.26 (1H, s), 7.36 (2H, d), 7.89 (2H, s), 8.55 (2H, d), 9.03 (1H, s), 9.29 (1H, t), 10.85 (1H, s).

LC/MS, $t = 2.96$ min, $[MH^+]$ 442 and 444.

Example 23: 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzyl-amide

10



In a manner similar to Example 1(c) 2-(3-fluorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and 4-fluorobenzylamine hydrochloride (22.5 mg) afforded the title compound (31 mg).


15

NMR (400MHz, DMSO- d_6) δ 4.46 (2H, d), 6.88 (1H, t), 7.19 (2H, t), 7.35-7.45 (3H, m), 7.53 (1H, d), 7.78 (1H, d of t), 8.89 (1H, s), 9.15 (1H, t), 10.65 (1H, s).

LC/MS, $t = 3.49$ min, $[MH^+]$ 409.

Example 24: 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzyl-amide

20



In a manner similar to Example 1(c) 2-(3-bromophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and 4-fluorobenzylamine hydrochloride (19 mg) afforded the title compound (31 mg).


25

NMR (400MHz, DMSO- d_6) δ 4.44 (2H, d), 7.15-7.25 (3H, m), 7.31 (1H, t), 7.4 (2H, m), 7.71 (1H, d), 8.10 (1H, s), 8.88 (1H, s), 9.14 (1H, t), 10.60 (1H, s).

LC/MS, $t = 3.65$ min, $[MH^+]$ 469 and 471.

30

Example 25: 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzyl-amide




In a manner similar to Example 1(c) 2-(3,5-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (33 mg) and 4-fluorobenzylamine hydrochloride (17 mg) afforded the title compound (33 mg).

NMR (400MHz, DMSO-d₆) δ 4.44 (2H, d), 7.19 (2H, t), 7.26 (1H, s), 7.40 (2H, t), 7.88 (2H, s), 8.94 (1H, s), 9.16 (1H, t), 10.80 (1H, s).

LC/MS, t = 3.87 min, [MH⁺] 459 and 457.

Example 26: 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-cyanobenzylamide



In a manner similar to Example 1(c) 2-(3,5-dichlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and 4-cyanobenzylamine (20 mg) afforded the title compound (33 mg).

NMR (400MHz, DMSO-d₆) δ 4.55 (2H, d), 7.26 (1H, s), 7.56 (2H, d), 7.84 (2H, d), 7.88 (2H, s), 8.99 (1H, s), 9.27 (1H, t), 10.80 (1H, s).


LC/MS, t = 3.74 min, [MH⁺] 466 and 468.

Example 27: 2-(4-Cyano-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide


(a). In a manner similar to Example 1(a) benzyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.5 g) and 4-aminobenzonitrile (0.93 g) afforded, after silica gel chromatography using 3:2 isohexane:ethyl acetate, benzyl 2-(4-cyanophenyl-amino)-4-trifluoromethylpyrimidine-5-carboxylate (323 mg).

NMR (400MHz, CDCl₃) δ 5.39 (2H, s), 7.35-7.5 (5H, m), 7.68 (2H, d), 7.76 (1H, s), 7.84 (2H, d), 9.10 (1H, s).


LC/MS CF100603-1, t = 3.39 min, [MH⁺] 399.




- (b). To a solution of benzyl 2-(4-cyanophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylate (323 mg) in dimethylformamide (6 ml) was added 10% palladium on charcoal (wet) and the mixture stirred under atmospheric hydrogenation conditions for 4 h. Catalyst was filtered through a 1 μ M PTFE filter and filtrate evaporated under reduced pressure. The residual solid was
- 5 trituted with ether, filtered and dried *in vacuo* at 50°C to afford 2-(4-cyanophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (284 mg).
- NMR (400MHz, DMSO-d₆) δ 7.84 (2H, d), 7.99 (2H, d), 9.13 (1H, s), 11.1 (1H, s), 13.8 (1H, br s). LC/MS CF100887-1, t = 2.78 min, [MH⁺] 309.



- 10 (c) In a manner similar to example 1(c), 2-(4-cyanophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid and benzylamine afforded the title compound LC/MS, t = 3.02 min, [MH⁺] 398.



- 15 **Example 28: 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-methyl-pyridin-4-ylmethyl)-amide hydrochloride**



- 20 To a solution of 2-(3-chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-methyl-pyridin-4-ylmethyl)-amide (15 mg) in ethanol (2 ml) was added a few drops of concentrated hydrochloric acid. The solution was stirred at room temperature for 0.5 h and then evaporated under reduced pressure. Trituration with ether precipitated a white solid which was filtered off, washed with fresh ether and dried to afford the title compound (14 mg).
- 25 NMR (400MHz, DMSO-d₆) δ 2.72 (3H, s), 4.67 (2H, d), 7.12 (1H, d), 7.38 (1H, t), 7.67 (1H, d), 7.75 (1H, d), 7.79 (1H, s), 8.00 (1H, s), 8.71 (1H, d), 9.06 (1H, s), 9.49 (1H, t), 10.70 (1H, s) LC/MS, t = 2.62 min, [MH⁺] 422 and 424.


- 30 **Example 29: 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-pyridin-4-ylmethyl)-amide.**

(a). 4-Bromomethyl-2-fluoro-pyridine.

To a solution of 2-fluoro-4-methylpyridine (1.0 g, ex Lancaster) in carbon tetrachloride (10 ml) was added N-bromosuccinimide (1.6 g, ex Lancaster) and 1,1'- azobis (cyclohexanecarbonitrile) (100 mg, ex Aldrich). The mixture was then refluxed for 24h. Carbon tetrachloride was removed under reduced pressure and the crude oily solid was used in the next stage without purification. LC/MS, t = 2.38 min, [MH⁺] 190 and 192.

(b). (2-Fluoro-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester.


To crude 4-bromomethyl-2-fluoro-pyridine in an ice bath was added 25% ammonia solution (10 ml, ex BDH) and the mixture stirred at 0° for 5h. Ammonia solution was removed under reduced pressure and the yellow oily solid residue dissolved in dichloromethane (10 ml) and dimethylformamide (1 ml). The solution was cooled in an ice bath and triethylamine (1.5 ml, ex BDH) was added followed by di-tert-butyl dicarbonate (1.0 g, ex Avocado). The solution was stirred at 0° for 1h and then the dichloromethane removed under reduced pressure. The residue was dissolved in ethyl acetate and washed twice with water, dried (MgSO₄) and evaporated to give a yellow oil. This was purified by Biotage chromatography (100 g, silica column) eluting with 30% ethyl acetate in hexane to afford the title compound as a white solid (358 mg). NMR (400MHz, DMSO-d₆) δ 1.40 (9H, s), 4.20 (2H, d), 6.97 (1H, s), 7.20 (1H, d), 7.60 (1H, t), 8.17 (1H, d) LC/MS, t = 2.60 min, [M - Me₂C=CH₂ + H]⁺ 171



(c). C-(2-Fluoro-pyridin-4-yl)-methanamine dihydrochloride.

(2-Fluoro-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester (350mg) was treated at room temperature with 4N hydrochloric acid in 1,4-dioxan (5 ml) and stirred for 2h. The white precipitate was filtered, washed with fresh ether and dried to afford the title compound (200 mg). NMR (400MHz, DMSO-d₆) δ 4.14 (2H, d), 7.38 (1H, s), 7.51 (1H, d), 8.28 (1H, d), 8.82 (3H, s).

(d). 2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-pyridin-4-ylmethyl)-amide



In a manner similar to Example 1(c) 2-(3-chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (75 mg) and C-(2-fluoro-pyridin-4-yl)-methylamine dihydrochloride (56 mg) afforded the title compound (85 mg).

- 5 NMR (400MHz, DMSO-d₆) δ 4.55 (2H, d), 7.10 (2H, m), 7.38 (2H, m), 7.66 (1H, m), 7.98 (1H, m), 8.21 (1H, d), 8.99 (1H, s), 9.29 (1H, t), 10.65 (1H, s)
LC/MS, t = 3.33 min, [MH⁺] 426 and 428.

Examples 30- 42

10

In the following table giving examples 30 to 42, columns 1 and 2 give precursors that were reacted in a manner similar to that in example 1(a). In a manner similar to that in example 1(b), the carboxylic acid of the resultant ester was prepared. Finally, in a manner similar to that of example 1(c), the resultant acid product was reacted with the precursor of column 3 to provide the final product of column 4.

15


	1	2	3	4 - Product	LCMS data 1) Retention time 2) MH ⁺ 3) Formula consistent with MH ⁺
30	Benzyl 2-chloro-4-(trifluoromethyl)pyrimidine-5-carboxylate	m-Anisidine	Benzylamine	2-(3-Methoxy-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide	3.08 min 403 C ₂₀ H ₁₇ F ₃ N ₄ O ₂
31	Benzyl 2-chloro-4-(trifluoromethyl)pyrimidine-5-carboxylate	o-Anisidine	Benzylmethylamine	2-(2-Methoxy-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide	3.25 min 417 C ₂₁ H ₁₉ F ₃ N ₄ O ₂
32	Benzyl 2-chloro-4-(trifluoromethyl)	m-Anisidine	Benzylmethylamine	2-(3-Methoxy-phenylamino)-4-	3.19 min 417

	pyrimidine-5-carboxylate			trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl -amide	$C_{21}H_{19}F_3N_4O_2$
33	Benzyl 2-chloro-4-(Trifluoromethyl)pyrimidine-5-carboxylate	3-Chloroaniline	4-Chlorobenzylamine	2-(3-Chlorophenylamino)- 4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-chloro-benzylamide	3.75 min 441 $C_{19}H_{13}^{35}Cl_2F_3N_4O$
34	Benzyl 2-chloro-4-(Trifluoromethyl)pyrimidine-5-carboxylate	3-Chloroaniline	N-ethylbenzylamine	2-(3-Chlorophenylamino)- 4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-ethyl-amide	3.68 min 435 $C_{21}H_{18}^{35}ClF_3N_4O$
35	Methyl 2-chloro-4-(Trifluoromethyl)pyrimidine-5-carboxylate	2,3-Dichloroaniline	Benzylamine	2-(2,3-Dichlorophenylamino)- 4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide	3.63 min 441 $C_{19}H_{13}^{35}Cl_2F_3N_4O$
36	Methyl 2-chloro-4-(Trifluoromethyl)pyrimidine-5-carboxylate	3-Fluoroaniline	Benzylmethylamine	2-(3-Fluorophenylamino)- 4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide	3.55 min 405 $C_{20}H_{16}F_4N_4O$
37	Methyl 2-chloro-4-(Trifluoromethyl)pyrimidine-5-carboxylate	3-Chloroaniline	4-Isobutylbenzylamine	2-(3-Chlorophenylamino)- 4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-isobutyl-benzylamide	4.07 min 463 $C_{23}H_{22}^{35}ClF_3N_4O$
38	Methyl 2-Chloro-4-(trifluoromethyl)pyrimidine-5-carboxylate	3-Chloroaniline	C-(2-Methylpyridin-4-yl)-methylamine	2-(3-Chlorophenylamino)-4-trifluoromethyl-pyrimidine-5-	2.65 min 422 $C_{19}H_{15}^{35}ClF_3N$

				carboxylic acid (2-methyl- pyridin-4- ylmethyl)-amide	⁵ O
39	Methyl 2-Chloro- 4-(trifluoromethyl) pyrimidine-5- carboxylate	3-Bromoaniline	C-(2-Methyl- pyridin-4-yl)- methylamine	2-(3-Bromo- phenylamino)-4- trifluoromethyl- pyrimidine-5- carboxylic acid (2-methyl- pyridin-4- ylmethyl)-amide	2.68 min 466 $C_{19}H_{15}^{79}Br$ F_3N_5O
40	Benzyl 2-chloro- 4-(trifluoromethyl) pyrimidine-5- carboxylate	2-Chloroaniline	N-Benzyl-N- methylamine	2-(2-Chloro- phenylamino)-4- trifluoromethyl- pyrimidine-5- carboxylic acid N-benzyl-N- methyl-amide	3.24 min 421 $C_{20}H_{16}^{35}ClF_3N$ 4O
41	Methyl 2-chloro- 4-(trifluoromethyl) pyrimidine-5- carboxylate	3-Fluoroaniline	N-(4- Aminomethyl)- benzonitrile, compound with hydrochloric acid.	2-(3-Fluoro- phenylamino)-4- trifluoromethyl- pyrimidine-5- carboxylic acid N-(4-cyano- benzyl)amide	3.37 min 416 $C_{20}H_{13}F_4N_5O$
42	Methyl 2-chloro- 4- (trifluoromethyl)p yrimidine-5- carboxylate	2,4- dichloroaniline	C-Pyrimidin-4- yl-methylamine (bought from Manchester Organics ltd)	2-(2,4-Dichloro- phenylamino)-4- trifluoromethyl- pyrimidine-5- carboxylic acid N-(pyrimidin-4- ylmethyl)-amide	3.00 min 442 $C_{18}H_{12}^{35}Cl_2F_3$ N_5O

Table 1

Examples 43 to 78 were prepared in a corresponding fashion to the above compounds.



5

Example no	name	R ¹	R ³	Z	LC/MS 1)Retention time (min) 2)MH ⁺ 3)Formula
43	2-(2-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzylamide	H	Ph	2-Cl	3.11 min 407 C ₁₉ H ₁₄ ³⁵ ClF ₃ N ₄ O
44	2-(4-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzylamide	H	Ph	4-Cl	3.25 min 407 C ₁₉ H ₁₄ ³⁵ ClF ₃ N ₄ O
45	2-(4-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide	Me	Ph	4-Cl	3.35 min 421 C ₂₀ H ₁₆ ³⁵ ClF ₃ N ₄ O
46	2-(4-Methoxy-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzylamide	H	Ph	4-MeO	3.02 min 402 C ₂₀ H ₁₇ F ₃ N ₄ O ₂
47	2-(4-Methoxy-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide	Me	Ph	4-MeO	3.13 min 416 C ₂₁ H ₁₉ F ₃ N ₄ O ₂
48	2-(3-Cyano-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide	Me	Ph	3-CN	3.13 min 412 C ₂₁ H ₁₆ F ₃ N ₅ O
49	2-(4-Cyano-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide	Me	Ph	4-CN	3.12 min 412 C ₂₁ H ₁₆ F ₃ N ₅ O

50	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(3-methoxybenzyl)amide	H	3-MeO Ph	3-Cl	3.58 min 437 $C_{20}H_{16}^{35}Cl$ $F_3N_4O_2$
51	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(2-chlorobenzyl)amide	H	2-Cl-Ph	3-Cl	3.72 min 441 $C_{19}H_{13}^{35}Cl_2F$ $_3N_4O$
52	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(3-chlorobenzyl)amide	H	3-Cl- Ph	3-Cl	3.75 min 441 $C_{19}H_{13}^{35}Cl_2F$ $_3N_4O$
53	2-(2-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-ethyl-amide	Et	Ph	2-Cl	3.68 min 435 $C_{21}H_{18}^{35}Cl$ F_3N_4O
54	2-(2,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide	Me	Ph	2,4-diCl	3.79 min 455 $C_{20}H_{15}^{35}Cl_2F$ $_3N_4O$
55	2-(3,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide	Me	Ph	3,4-diCl	3.87 min 455 $C_{20}H_{15}^{35}Cl_2F$ $_3N_4O$
56	2-(2,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzylamide	H	Ph	2,5-diCl	3.68 min 441 $C_{19}H_{13}^{35}Cl_2$ F_3N_4O
57	2-(3,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide	Me	Ph	3,5-diCl	3.93 min 455 $C_{20}H_{15}^{35}Cl_2$ F_3N_4O
58	2-(2,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-benzyl-N-methyl-amide	Me	Ph	2,5-diCl	3.78 min 455 $C_{20}H_{15}^{35}Cl_2$ F_3N_4O

59	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(pyridin-2-ylmethyl)-amide	H	2-pyridinyl	3-Cl	3.28 min 408 $C_{18}H_{13}^{35}Cl$ F_3N_5O
60	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(pyridin-3-ylmethyl)-amide	H	3-pyridinyl	3-Cl	3.07 min 408 $C_{18}H_{13}^{35}Cl$ F_3N_5O
61	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(3,5-difluoro-benzyl)amide	H	3,5-diF-Ph	3-Cl	3.73 min 443 $C_{19}H_{12}^{35}Cl$ F_5N_4O
62	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-trifluoromethoxy-benzyl)amide	H	4-CF ₃ O-Ph	3-Cl	3.87 min 491 $C_{20}H_{13}^{35}Cl$ $F_6N_4O_2$
63	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-bromo-benzyl)amide	H	4-Br-Ph	3-Cl	3.84 min 485 $C_{19}H_{13}^{79}Br^{35}Cl$ F_3N_4O
64	2-(3-Bromo-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-cyano-benzyl)amide	H	4-CN-Ph	3-Br	3.54 min 476 $C_{20}H_{13}^{79}Br$ F_3N_5O
65	2-(2,3-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-cyano-benzyl)amide	H	4-CN-Ph	2,3-diCl	3.54 min 466 $C_{20}H_{12}^{35}Cl_2F$ $_3N_5O$
66	2-(2,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-cyano-benzyl)amide	H	4-CN-Ph	2,4-diCl	3.58 min 466 $C_{20}H_{12}^{35}Cl_2F$ $_3N_5O$
67	2-(2,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-cyano-benzyl)amide	H	4-CN-Ph	2,5-diCl	3.57 min 466 $C_{20}H_{12}^{35}Cl_2F$ $_3N_5O$

68	2-(3,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-cyano-benzyl)amide	H	4-CN-Ph	3,4-diCl	3.68 min 466 $C_{20}H_{12}^{35}Cl_2F_3N_5O$
69	2-(2,6-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(pyridin-4-ylmethyl)-amide	H	4-pyridinyl	2,6-diCl	2.54 min 442 $C_{18}H_{12}^{35}Cl_2F_3N_5O$
70	2-(2,6-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-fluoro-benzyl)amide	H	4-F-Ph	2,6-diCl	3.44 min 459 $C_{19}H_{12}^{35}Cl_2F_4N_4O$
71	2-(2,6-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-cyano-benzyl)amide	H	4-CN-Ph	2,6-diCl	3.32 min 466 $C_{20}H_{12}^{35}Cl_2F_3N_5O$
72	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(2-chloro-4-fluoro-benzyl)amide	H	2-Cl, 4-F-Ph	3-Cl	3.75 min 459 $C_{19}H_{12}^{35}Cl_2F_4N_4O$
73	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (3-chloro-4-fluoro-benzyl)amide	H	3-Cl, 4-F-Ph	3-Cl	3.76 min 459 $C_{19}H_{12}^{35}Cl_2F_4N_4O$
74	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-fluoro-2-trifluoromethyl-benzyl)amide	H	2-CF ₃ -4-F-Ph	3-Cl	3.80 min 493 $C_{20}H_{12}^{35}ClF_7N_4O$
75	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-fluoro-3-trifluoromethyl-benzyl)amide	H	3-CF ₃ -4-F-Ph	3-Cl	3.79 min 493 $C_{20}H_{12}^{35}ClF_7N_4O$
76	2-(3-Fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(pyrimidin-4-ylmethyl)-amide	H	pyrimidinyl	3-F	2.89 min 393 $C_{17}H_{12}F_4N_6O$

77	2-(3-Fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(2-methyl-pyridin-4-ylmethyl)-amide	H	2-Me-4-pyridinyl	3-F	2.48 min 406 C ₁₉ H ₁₅ F ₄ N ₅ O
78	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(4-methyl-benzyl)amide	H	4-MePh	3-Cl	3.75 min 421 C ₂₀ H ₁₆ ³⁵ Cl F ₃ N ₄ O






Table 2








Examples 79 to 114 were prepared in a manner analogous to example 1.

5







Example No.	Name	Structure	LC/MS 1)Retention time (min) 2)MH ⁺ 3)Formula
79	2-(3-Fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide		3.49 409 C ₁₉ H ₁₃ F ₅ N ₄ O
80	2-(3-Bromo-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide		3.65 471 C ₁₉ H ₁₃ ⁸¹ BrF ₄ N ₄ O
81	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 3,4-difluoro-benzylamide		3.66 443 C ₁₉ H ₁₂ ³⁵ ClF ₅ N 4O
82	2-(3-Chloro-4-fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide		3.61 443 C ₁₉ H ₁₂ ³⁵ ClF ₅ N 4O
83	2-(3-Chloro-2-fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide		3.51 443 C ₁₉ H ₁₂ ³⁵ ClF ₅ N 4O

84	2-(5-Chloro-2-fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide		3.54 443 $C_{19}H_{12}^{35}ClF_5N_4O$
85	2-(3,5-Difluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide		3.55 427 $C_{19}H_{12}F_6N_4O$
86	2-(3-Chloro-4-cyano-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide		3.52 450 $C_{20}H_{12}^{35}ClF_4N_5O$
87	2-(3-Methoxy-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (pyridin-4-ylmethyl)-amide		2.53 404 $C_{19}H_{16}F_3N_5O_2$
88	2-(3-Bromo-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoropyridin-4-ylmethyl)-amide		3.37 472 $C_{18}H_{12}^{81}BrF_4N_5O$
89	2-(3-Fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoropyridin-4-ylmethyl)-amide		3.18 410 $C_{18}H_{12}F_5N_5O$

90	2-(2,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoropyridin-4-ylmethyl)-amide		3.41 460 $C_{18}H_{11}^{35}Cl_2F_4$ N_5O
91	2-(3,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoropyridin-4-ylmethyl)-amide		3.61 460 $C_{18}H_{11}^{35}Cl_2F_4$ N_5O
92	2-(3,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoropyridin-4-ylmethyl)-amide		3.54 460 $C_{18}H_{11}^{35}Cl_2F_4$ N_5O
93	2-(2,6-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoropyridin-4-ylmethyl)-amide		3.13 460 $C_{18}H_{11}^{35}Cl_2F_4$ N_5O
94	2-(2,3-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoropyridin-4-ylmethyl)-amide		3.38 460 $C_{18}H_{11}^{35}Cl_2F_4$ N_5O

95	2-(2,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoropyridin-4-ylmethyl)-amide		3.48 460 $C_{18}H_{11}^{35}Cl_2F_4$ N_5O
96	2-(2-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylmethyl-amide		3.24 421 $C_{20}H_{16}^{35}ClF_3N$ $_4O$
97	2-(3-Cyano-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide		3.02 398 $C_{20}H_{14}F_3N_5O$
98	2-(2,6-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide		3.42 441 $C_{19}H_{13}^{35}Cl_2F_3$ N_4O
99	2-(2,3-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluorobenzylamide		3.66 459 $C_{19}H_{12}^{35}Cl_2F_4$ N_4O
100	2-(2,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluorobenzylamide		3.71 459 $C_{19}H_{12}^{35}Cl_2F_4$ N_4O
101	2-(2,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluorobenzylamide		3.70 459 $C_{19}H_{12}^{35}Cl_2F_4$ N_4O

102	2-(3,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide		3.80 459 $C_{19}H_{12}^{35}Cl_2F_4$ N_4O
103	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2,4-difluoro-benzylamide		3.63 443 $C_{19}H_{12}^{35}ClF_5N$ $4O$
104	2-(3-Fluoro-4-trifluoromethyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide		3.72 477 $C_{20}H_{12}F_8N_4O$
105	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-carbamoyl-benzylamide		3.16 450 $C_{20}H_{15}^{35}ClF_3N$ $5O_2$
106	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-tert-butyl-benzylamide		4.00 463 $C_{23}H_{22}^{35}ClF_3N$ $4O$
107	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-Boc-4-amino- benzylamide		3.77 522 $C_{24}H_{23}^{35}ClF_3N$ $5O_3$
108	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid ((R)-1-phenyl-ethyl)-amide		3.64 421 $C_{20}H_{16}^{35}ClF_3N$ $4O$

109	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 3-chloro,4-fluoro- benzylamide		3.76 459 $C_{19}H_{12}^{35}Cl_2F_4$ N_4O
110	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (4-fluoro-benzyl)-methyl-amide		3.67 439 $C_{20}H_{15}^{35}ClF_4N$ $_4O$
111	2-(3-Chloro-4-trifluoromethoxy-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide		3.82 509 $C_{20}H_{12}^{35}ClF_7N$ $_4O_2$
112	{3-[(4-Fluoro-benzylcarbamoyl)-trifluoromethyl-pyrimidin-2-ylamino]-phenyl}-acetic acid		3.18 449 $C_{21}H_{16}F_4N_4O_3$
113	3-Chloro-5-[(4-fluoro-benzylcarbamoyl)-trifluoromethyl-pyrimidin-2-ylamino]-benzoic acid		3.62 469 $C_{20}H_{13}^{35}ClF_4N$ $_4O_3$
114	2-(3,5-Ditrifluoromethyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 4-fluoro-benzylamide		3.92 527 $C_{21}H_{12}F_{10}N_4O$

Example 115: Preparation of Nanomilled Compound

- 5 2.5 g of a compound is weighed into a 10 ml centrifuge tube. 10 ml of 0.3mm YTZ milling beads (Manufacturer, batch no.) are weighed into a 50 ml milling pot. 22.5 ml of aqueous 1.5% HPMC is measured with a measuring cylinder into a 100 ml beaker. This solution is homogenised for 3 seconds with an Ultra Turrax T25 homogeniser. Approximately 200 mg of the 2.5 g of the compound is added to the HPMC solution and homogenised at the lowest speed setting until the
- 10 powder is wetted. This is repeated until all the compound is added. The speed of the

- homogeniser is then increased to maximum and the suspension is homogenised for a further 3 minutes. This suspension is allowed to stand for 30 minutes in order to allow some of the foam to disperse. The suspension is then poured into the 50 ml pot containing the YTZ milling beads, stirring to release any trapped air. The lid to the pot is then fitted and the pot sealed with some
- 5 Nesco film. This procedure is repeated for a second 50 ml nanomilling pot and both pots are placed on a Retsch mill and milled for a total of 8 hours.

- The milling pots are removed from the Retsch mill and left to cool and for the foam to disperse overnight. In the morning the suspension and bead mixture is passed through a 200 μ , 40 mm diameter screen. The contents from each 50 ml pot is washed with aqueous 1.5% HPMC: 10% of
- 10 the original suspension volume (i.e. 2.5 ml). The suspension from the 2 pots is combined to make 1 batch. The suspension obtained from the method above is named the concentrate.

The concentrate is diluted 1 in 4 with aqueous 1.5% HPMC to give a nominal concentration of 25 mg/ml. This first dilution is assayed by HPLC to calculate the actual concentration

HPLC conditions

- 15 Column: Symmetry C₁₈ 5 μ 3.9x150 mm column; flow rate 1.0 ml/min; column temp 40°C.; UV detection at 280nm.

Mobile phase gradient: A: water + 0.1% trifluoro acetic acid (TFA)

B: acetonitrile + 0.1% TFA

Table A: HPLC gradient

Time (min.)	A (%)	B (%)
0	90	10
15	10	90
20	10	90
20.1	90	10
30	90	10

20

A particle size analysis is carried out on the Lecotrac laser particle size analyser and compared to the results from the starting material for comparison.

- Formulations for pharmaceutical use incorporating compounds of the present invention either pre or post nanomilling can be prepared in various forms and with numerous excipients.
- 25 Examples of such formulations are given below.

Example 116: Inhalant Formulation

A compound of formula (I) or a pharmaceutically acceptable derivative thereof, (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.

5 **Example 117: Tablet Formulation**

	<u>Tablets/Ingredients</u>	<u>Per Tablet</u>
	1. Active ingredient (Compound of formula (I) or pharmaceutically acceptable derivative)	40 mg
10	2. Corn Starch	20 mg
	3. Alginic acid	20 mg
	4. Sodium Alginate	20 mg
	5. Mg stearate	1.3 mg

15

Procedure for tablet formulation:

Ingredients 1, 2, 3 and 4 are blended in a suitable mixer/blender. Sufficient water is added portion-wise to the blend with careful mixing after each addition until the mass is of a consistency to permit its conversion to wet granules. The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen. The wet granules are then dried in an oven at 140°F (60°C) until dry. The dry granules are lubricated with ingredient No. 5, and the lubricated granules are compressed on a suitable tablet press.


25 **Example 118: Parenteral Formulation**

A pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of formula (I) in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then rendered sterile by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

30

Claims

1. A compound of formula (I):



10

wherein:


Y is phenyl, substituted with one, two or three substituents;

R¹ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, and halosubstituted C₁₋₆ alkyl;

R² is C(R⁷)₂R³;

R³ is an optionally substituted 5- to 6- membered aromatic heterocyclyl group, or group

15 A:



R⁴ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, or halosubstituted C₁₋₆ alkyl, COCH₃, and SO₂Me;

20 R⁶ is methyl, chloro or CH_xF_n wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3;

R_a can be independently selected from hydrogen, fluoro, chloro or trifluoromethyl;

R_b can be independently be selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, haloC₁₋₆ alkoxy, hydroxy, cyano, halo, sulfonyl, CONH₂, COOH or NHCOOC₁₋₆alkyl;

25 R⁷ can be independently hydrogen or C₁₋₆ alkyl;

or a pharmaceutically acceptable derivative thereof.

with the proviso that the compounds are not

2-(4-*tert*-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide;

2-(4-*tert*-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzyl-methyl-
30 amide;

2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-methoxy-
benzylamide;

2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-bromo-
benzylamide.

35

2. A compound as claimed in claim 1 selected from any one of examples 1 to 114 or a pharmaceutically acceptable derivative thereof.

3. A pharmaceutical composition comprising a compound as claimed in claim 1 or 2 or a pharmaceutically acceptable derivative thereof.
- 5 4. A pharmaceutical composition as claimed in claim 3 further comprising a pharmaceutical carrier or diluent thereof.
- 10 5. A method of treating a human or animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) as claimed in claim 1 or 2 or a pharmaceutically acceptable derivative thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/09221

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/42 C07D401/12 A61K31/505 A61K31/506 A61P25/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 09315 A (SIGNAL) 13 March 1997 (1997-03-13) claims 1-4, 34-37 ---	1-4
P, X	WO 02 66036 A (BRISTOL-MYERS) 29 August 2002 (2002-08-29) page 1 -page 5; claims; examples 39, 42 -----	1-4

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

17 December 2003

Date of mailing of the international search report

02/01/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/09221

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 5 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/09221

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9709315	A	13-03-1997	US	5811428 A	22-09-1998
			AU	726058 B2	26-10-2000
			AU	7013096 A	27-03-1997
			AU	726522 B2	09-11-2000
			AU	7163196 A	27-03-1997
			CA	2230894 A1	13-03-1997
			CA	2230896 A1	13-03-1997
			EP	0850228 A1	01-07-1998
			JP	11512390 T	26-10-1999
			JP	11512399 T	26-10-1999
			WO	9709325 A1	13-03-1997
			WO	9709315 A1	13-03-1997
			US	5935966 A	10-08-1999

WO 0266036	A	29-08-2002	CA	2438231 A1	29-08-2002
			EP	1361879 A1	19-11-2003
			NO	20033683 A	17-10-2003
			WO	02066036 A1	29-08-2002
			US	2002183335 A1	05-12-2002
